Chukwudi Okeke
Primary Care · Plano, TXNPI 1518672096
Payments from drug & device makers
Across 148 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$746
- Corium, LLC$480
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$188
- Vanda Pharmaceuticals Inc.$168
- Otsuka America Pharmaceutical, Inc.$160
- Teva Pharmaceuticals USA, Inc.$146
- plus $666 from 11 others
What the payments were for
- Food & beverage$2,553100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $746 |
| Corium, LLC | 21 | $480 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $188 |
| Vanda Pharmaceuticals Inc. | 5 | $168 |
| Otsuka America Pharmaceutical, Inc. | 9 | $160 |
| Teva Pharmaceuticals USA, Inc. | 5 | $146 |
| Neurocrine Biosciences, Inc. | 4 | $119 |
| Johnson & Johnson | 5 | $99 |
| Alkermes, Inc. | 4 | $86 |
| Lundbeck LLC | 5 | $86 |
| Bausch Health US, LLC | 5 | $83 |
| Tris Pharma Inc | 3 | $54 |
| Neos Therapeutics, LP | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Tempus AI, Inc | 1 | $19 |
| Indivior Inc. | 1 | $15 |
How this compares
$2,553 in reported general payments places this provider in the 85th percentile of 563 primary care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $616 |
| Hydroxyzine Pamoate | 36 | $586 |
| Quetiapine Fumarate | 14 | $330 |
| Escitalopram Oxalate | 16 | $255 |
| Trazodone Hcl | 17 | $254 |
| Duloxetine Hcl | 17 | $251 |
| Buspirone Hcl | 16 | $204 |
| Olanzapine | 12 | $199 |
| Gabapentin | 18 | $191 |
| Bupropion XlBupropion Hcl | 16 | $188 |
| Alprazolam | 25 | $118 |
| Zolpidem Tartrate | 19 | $117 |
| Sertraline Hcl | 12 | $72 |
Paid to pharmacies, not to this prescriber.
Other primary care in Plano
- Maya AjiPlano$6K
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Roxana RoposGrapevine$13K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.